The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Medway setup a state-of-the-art Heart Institute in Chennai
The company received gross proceeds of approximately US$1.7 million and net proceeds,
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Subscribe To Our Newsletter & Stay Updated
